Pluto Bioinformatics

GSE116907: Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq)

Bulk RNA sequencing

Three triple negative breast cancer cell lines (MDAMB231, SUM159, and HCC1806) were treated with small molecule inhibitors (JQ1, BET bromodomain inhibitor; GSK2801, BAZ2A/B bromodomain inhibitor) alone and in combination for 72 hours SOURCE: Gary,L,Johnson (glj@med.unc.edu) - Gary L. Johnson UNC Chapel Hill SOM